Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Stocks Extend Slump as Tech Rout Deepens

View original at nasdaq.com
Stocks Extend Slump as Tech Rout Deepens The S&P 500 Index ($SPX) (SPY) today is down -0.50%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.40%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Supported last week's Fed decision to hold interest rates steady because of risks tilted toward higher inflation

    80% confidence

  • S&P earnings growth expected to climb by +8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth

    80% confidence

  • The economy remains resilient in a challenging global environment with uncertain outlook due to trade policy and geopolitical tensions

    80% confidence

  • Risks are tilted toward higher inflation and it is essential to maintain credibility by returning to a disinflationary path

    80% confidence

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings expected to increase by +4.6%

    80% confidence

  • Upside risks to inflation have diminished and there should be scope for further policy easing if economy and inflation evolve as expected

    80% confidence

Data points we hold from this source

Qualcomm Incorporated · revenue10600000000 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Stocks Extend Slump as Tech Rout Deepens — Source | Via News | ViaNews Market